Facebook
X
LinkedIn
ForwardImplementing Quality and Value in HCT
The predicted growth in healthcare spending augments pressure by those within the healthcare system to contain costs and focus on quality and value of healthcare. Hematopoietic cell transplantation (HCT) represents only a fraction of the total dollars spent on healthcare but it is an expensive therapy and increases in transplant related expenditures are rising faster than other areas of healthcare.
This forum is the fourth installment in a series of meetings designed to understand, plan and implement quality and value initiatives in the HCT community. The initiatives will address patient-centered care coordination, quality of life, facilitating centers’ quality improvement efforts, emerging reimbursement models and early referral to transplant.
The Medical College of Wisconsin designates this activity for up to 11 hours of participation for continuing education for allied health professionals.
Target Audience
Learning Objectives
At the conclusion of this activity, learners will be able to:
- Describe the need for quality and value initiatives within the HCT community to drive patient centered high-value healthcare
- Identify a consensus of quality and value initiatives in HCT, particularly, patient-centered care coordination, early referral to transplant and emerging reimbursement models.
- Develop actionable next steps to implement the selected quality and value initiatives.
| Name | Company | Role |
| Krishna Komanduri, MD | Novartis | Committee member |
| Richard Maziarz, MD | Athersys, Inc. Novartis, Incyte | Consultant, Advisory Board |
| Daniel Weisdorf, MD | Kadmon, Enivex | Consultant |
| Nandita Khera | Novartis | Consultant |
| Brennan McNally | United Health Group | Employee |
| Anthony Bonagura | Optum, Inc. | Employee |
| Navneet Majhal | Anthem, Inc. | Committee Member |
Available Credit
- 11.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 11.00 Hours of ParticipationHours of Participation credit.